Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy

Journal of Clinical Microbiology

Volumn 36, Issue 4, 1998, Pages 1056-1063

  Tedder, Richard S ^a   Kaye, Steve ^a,e   Loveday, Clive ^b   Weller, Ian V D ^a   Jeffries, Don ^c   Norman, Jane ^c   Weber, Jonathan ^d   Bourelly, Michel ^d   Foxall, Russell ^d   Babiker, Abdel ^e   Darbyshire, Janet H ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; TREATMENT OUTCOME; VIREMIA; VIRUS CULTURE; VIRUS LOAD;

EID: 0031919124     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.36.4.1056-1063.1998     Document Type: Article

References (30)

1. Aoki-Sei, S., R. Yarchoan, S. Kageyama, D. T. Hoekzema, J. M. Pluda, K. M. Wyvill, S. Broder, and H. Mitsuya. 1992. Plasma HIV-1 viraemia in HIV-1 infected individuals assessed by polymerase chain reaction. AIDS Res. Hum. Retroviruses 8:1263-1270.
2. Bieniasz, P. D., K. Ariyoshi, M. A. D. Bourelly, S. Bloor, R. B. Foxall, E. C. Harwood, and J. N. Weber. 1993. Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1 infected individuals. AIDS 7:803-806.
3. Boucher, C. A. B., E. O'Sullivan, J. W. Mulder, C. Ramaurtarsing, P. Kellam, G. Darby, J. M. A. Lange, J. Goudsmit, and B. A. Larder. 1992. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165:105-110.
4. Brun-Vezinet, F., D. Ingrand, J. Deforges, K. Gochi, F. Ferchal, M.-P. Schmitt, M. Jung, B. Masquelier, J. Aubert, C. Buffet-Janvresse, and H. Fleury. 1992. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J. Virol. Methods 37:177-188.
5. Byrnes, V. W., V. V. Sardana, W. A. Schleif, J. A. Condra, J. A. Wolfgang, W. J. Long, and C. L. Schneider. 1993. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrob. Agents Chemother. 27:1576-1579.
6. Cao, Y., D. D. Ho, J. Todd, R. Kokka, M. Urdea, J. D. Lifson, M. Piatak, S. Chen, B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995 Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res. Hum. Retroviruses 11:353-361.
7. Concorde Coordinating Committee. 1994. Concorde: MRC/ANRS randomised double blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343:871-881.
8. Coombs, R. W., A. C. Collier, J.-P. Allain, B. Nikora, M. Leuther, G. F. Gjerste, and L. Corey. 1989. Plasma viraemia in human immunodeficiency virus infection. N. Engl. J. Med. 321:1626-1631.
9. Delta Coordinating Committee. 1996. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 348: 283-291.
10. Fischl, M. A., D. D. Richman, N. Hansen, A. C. Collier, J. T. Carey, M. F. Para, D. Hardy, R. Dolin, W. G. Powderly, J. D. Allan, B. Wong, T. C. Merigan, V. J. McAuliffe, N. E. Hyslop, F. S. Rhane, N. H. Balfour, S. S. Spector, P. Volberding, C. Pettinelli, and J. Anderson. 1990. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV-1) infection. Ann. Intern. Med. 112:727-737.
11. Higuchi, R. 1989. Simple and rapid preparation of samples for PCR. In H. A. Erlich (ed.), PCR technology. Stockton Press, New York, N.Y.
12. Ho, D. D., T. Moudgil, and M. Alam. 1989. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321:1621-1625.
13. Holodniy, M., D. Katzenstein, M. Winters, J. Montoya, R. Shafer, M. Kozal, M. Ragni, and T. C. Merigan. 1993. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J. Acquired Immune Defic. Syndr. 6:366-369.
14. Katzenstein, D. A., M. Holodniy, D. M. Israelski, S. Sengupta, L. A. Mole, J. L. Bubp, and T. C. Merigan. 1992. Plasma viraemia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. J. Acquired Immune Defic. Syndr. 5:107-112.
15. Kaye, S., C. Loveday, and R. S. Tedder. 1992. A microtitre format point mutation assay: application to the detection of detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. J. Med. Virol. 4:214-246.
16. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type-1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
17. Kellam, P., and B. A. Larder. 1994. Recombinant vims assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
18. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
19. Larder, B. A., P. Kellam, and S. D. Kemp. 1991. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5:137-144.
20. Larder, B. A., A. Kohli, P. Kellam, S. D. Kemp, M. Kronide, and R. D. Henfrey. 1993. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 365:671-673.
21. Loveday, C., S. Kaye, M. Tenant-Flowers, M. Semple, U. Ayliffe, I. V. D. Weller, and R. S. Tedder. 1995. HIV-1 RNA serum load and resistant viral genotypes during early zidovudine therapy. Lancet 345:820-824.
22. Mellors, J. W., C. R. Rinaldo, P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
23. Meyerhans, A., R. Cheynier, J. Albert, M. Seth, S. Kwok, J. Sninsky, L. Morfeldt-Manson, B. Asjo, and S. Wain-Hobson. 1989. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 58:901-910.
24. Mulder, J., N. McKinney, C. Christopherson, J. Sninsky, L. Greenfield, and S. Kwok. 1994. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
25. Piatak, M., M. S. Saag, L. C. Yang, S. J. Clark, J. C. Kappes, K.-C. Luk, B. H. Hahn, G. M. Shaw, and J. D. Lifson. 1993. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259:1749-1754.
26. Semple, M. G., S. Kaye, C. Loveday, and R. S. Tedder. 1993. HIV-1 plasma viraemia quantification: a non-culture measurement needed for therapeutic trials. J. Virol. Methods 41:167-180.
27. Sheppard, H. W., M. S. Ascher, M. P. Busch, P. R. Sohmer, M. Stanley, M. C. Luce, J. A. Chimera, R. Madej, G. C. Rodgers, C. Lynch, H. Khayam-Bashi, E. L. Murphy, B. Eble, W. Z. Bradford, R. A. Royce, and W. Winkelstein. 1991. A multicenter proficiency trial of gene amplification (PCR) for the detection of HIV-1. J. Acquired Immune Defic. Syndr. 4:277-288.
28. Simmonds, P., P. Balfe, J. F. Peutherer, C. A. Ludlam, J. O. Bishop, and A. J. Leigh-Brown. 1990. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 64:864-872.
29. Van Gemen, B., R. van Beuningen, A. Nabbe, D. van Strijp, S. Jurriaans, P. Lens, and T. Kievits. 1994. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J. Virol. Methods 49:157-168.
30. Volberding, P. A., S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, H. H. Balfour, R. C. Reichman, J. A. Bartlett, M. A. Hirsch, R. L. Murphy, W. D. Hardy, R. Soeiro, M. A. Fischl, J. G. Bartlett, T. C. Merigan, N. E. Hyslop, D. D. Richman, F. T. Valentine, and L. Corey. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. N. Engl. J. Med. 322:941-949.